2023 World Conference on Lung Cancer (Posters)-EP13.03. A Single Arm Phase II Study of Tislelizumab Plus Anlotinib as Maintenance Therapy in Patients with Extensive-stage Small Cell Lung Cancer

EP13.03. A Single Arm Phase II Study of Tislelizumab Plus Anlotinib as Maintenance Therapy in Patients with Extensive-stage Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study presented the initial outcomes of a phase II study evaluating the efficacy and safety of combining tislelizumab and anlotinib as maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) after platinum-based chemotherapy. Eight patients who had achieved a complete or partial response or stable disease after first-line platinum-based treatment were enrolled in the study. The patients received anlotinib and tislelizumab until unacceptable toxicity, withdrawal, or disease progression.<br /><br />The primary endpoint of the study was the six-month progression-free survival (PFS) rate. Secondary and exploratory endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and duration of response (DoR), as well as safety.<br /><br />As of March 31, 2023, one patient achieved a partial response, and the disease control rate was 62.5%. The six-month PFS rate was 25% with a median PFS of 2.8 months. The median OS was 16.9 months. All patients experienced treatment-related adverse events, most of which were mild to moderate in severity.<br /><br />The study concludes that the combination of tislelizumab and anlotinib as maintenance therapy for ES-SCLC after first-line platinum-based chemotherapy showed promising efficacy and manageable safety.<br /><br />Overall, this study suggests that this treatment strategy could be a potential therapeutic option for patients with ES-SCLC after initial chemotherapy, but further investigation is needed to establish its effectiveness and safety in a larger patient population.

Asset Subtitle

YK Shi

Meta Tag

Speaker YK Shi

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

phase II study

efficacy

safety

tislelizumab

anlotinib

maintenance therapy

extensive-stage small cell lung cancer

platinum-based chemotherapy

progression-free survival

objective response rate